Casadale moreno baji

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate

Por um escritor misterioso
Last updated 07 julho 2024
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Full article: p38 MAPK inhibitors: a patent review (2012 – 2013)
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Figure 1 from 'Reverse' alpha-ketoamide-based p38 MAP kinase
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Molecules, Free Full-Text
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
p38 mitogen‐activated protein kinase: Functions and targeted
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
PDF] Structure-based design, synthesis, and biological evaluation
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Figure 2 from Switch control pocket inhibitors of p38-MAP kinase
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
New modifications to the area of pyrazole-naphthyl urea based p38
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Role of p38 MAP Kinase Signal Transduction in Solid Tumors - Hari
Recomendado para você
você pode gostar

© 2014-2024 rahh.de. All rights reserved.